Tag Archives: R&D

Research: Working Together Toward Cures

Jim Greenwood

Modern biomedical innovation and the discovery of new cures and therapies for devastating diseases require robust collaboration and coordination among industry, research institutions and physicians. By bringing together the brightest minds in medical research, our nation’s research enterprise has successfully brought hundreds of new drugs, biologics, and vaccines to market in recent years and developed a wealth of clinical prescribing information. Ongoing research is advancing the fight against some of humanity’s worst scourges, such as Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO 2012 Super Session Recap: Ernst & Young’s Beyond Borders

Ernst & Young

The fanfare surrounding this morning’s unveiling of Ernst & Young’s 26th annual report on the state of the biotech industry, Beyond Borders, was buoyed by positive trends outlined in the report that show despite the overall lingering uneasiness in the economy, biotech is continuing its growth momentum. The Super Session at the 2012 BIO International Convention was moderated by members of Ernst & Young’s life sciences leadership team: Glen Giovannetti, Gautam Jaggi and Sanjeev Wadhwa; Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Fireside Chat with Dr. Mikael Dolsten

Dolsten

Day two of the BIO CEO & Investor Conference kicked off with a Fireside Chat featuring Mikael Dolsten, MD, Phd, president, worldwide research & development from Pfizer, Inc and moderated by Mark Schoenebaum, senior biotechnology analyst with ISI Group. Speaking to a full room, Dr. Dolsten touched on Pfizer’s R&D priorities and their increased efforts to focus on investor capital return through a strong mixture of science, business and financial endeavors. In focusing on R&D, Pfizer has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , ,

Fireside Chat with Moncef Slaoui, GlaxoSmithKline

Dr. Moncel Slaoui

Moncel Slaoui, chairman of research and development (R&D) at GlaxoSmithKline (GSK), opened the 2012 BIO CEO & Investor Conference with a Fireside Chat where he provided insight in to his company’s biopharma R&D strategy. “GSK has announced that our R&D budget is no more a percentage of sales. If you think about it, it doesn’t make sense,” Slaoui stated, “because, sales are a marker of R&D 10 and 15 years ago.” Right now, GSK has Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Chairman Bernanke’s Speach on Government R&D Spending Policy and Economic Development

FED Chairman Ben Bernanke spoke about government funding of research and development at Georgetown University for the “New Building Blocks for Jobs and Economic Growth” conference. Highlights relating to Intellectual Property: 1.  “Economic policy affects innovation and long-run economic growth in many ways. A stable macroeconomic environment; sound public finances; and well-functioning financial, labor, and product markets all support innovation, entrepreneurship, and growth, as do effective tax, trade, and regulatory policies. Policies directed at objectives such as the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,